Cerulean Protein Tagging Enhances Immunogenicity and Osimertinib Response of Transplantable Murine EGFR Mutant Lung Cancer Cell Lines
Year: 2026
Type: preprint
Abstract: Lung cancers bearing mutations in epidermal growth factor receptors (EGFR) exhibit marked, but incomplete responses to tyrosine kinase inhibitors (TKIs) like osimertinib. We previously developed genetically-engineered mouse models (GEMMs) for EGFR exon 19 deletion (del19) and L860R (mouse equivalent of L858R). Sequences encoding mC3 cerulean fluorescent protein were included to mark emergent tumor cells. Orthotopic implantation of mEGFRdel19 cell lines into syngeneic C57BL/6J mice yielded tumors that were eliminated upon osimertinib therapy which is not typically observed in patients while mEGFR-L860R cell lines failed to establish tumors. Herein, mEGFRdel19 and mEGFR-L860R cell lines formed tumors in non-induced mEGFRdel19 and mEGFR-L860R GEMMs and green fluorescent protein-transgenic mice, supporting mC3-derived epitopes as mediators of immunoelimination. CRISPR-Cas9 mediated disruption of the mC3 cerulean sequence in established mEGFR cell lines yielded two independent mC3-deleted cell lines that formed orthotopic tumors and exhibited partial osimertinib responses. These studies provide a cautionary tale regarding use of fluorescent proteins in murine cancer models and reinforce host immunity as a participant in anti-tumor TKI responses initiated. These mC3-deleted cell lines serve as improved models to explore mechanisms of incomplete TKI response, acquired resistance and cancer cell interaction with the host immune microenvironment.
Institutions: University of Colorado Anschutz, University of Turku
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: EGFR-mutant lung cancer, osimertinib, tyrosine kinase inhibitors, immunogenicity, genetically engineered mouse models, EGFR exon 19 deletion, L858R mutation, orthotopic tumor transplantation, CRISPR/Cas9 gene deletion, host immunity, antitumor immunity, acquired drug resistance, tumor immune microenvironment
Open Access status: green
Awards: G1565180698, G5029337574
OpenAlex ID: W7236851559
